Jean Jacques Bienaime - Jun 1, 2024 Form 3 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Jun 1, 2024
Transactions value $
$0
Form type
3
Date filed
6/5/2024, 04:10 PM
Previous filing
May 22, 2024
Next filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KROS Common Stock 200 Jun 1, 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.